Clinical trials
Esophageal Carcinoma clinical trials
Below are recruiting esophageal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 246 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07086469RecruitingPhase 2
Surufatinib plus chemo-immunotherapy before chemoradiation for advanced esophageal cancer
This trial tests a new combination of treatments for people with advanced esophageal cancer that can't be removed by surgery. It uses a targeted therapy called surufatinib along with chemo-immunotherapy and radiation to see if it can shrink the tumor before further treatment.
Guangzhou, GuangdongAges 18–80 - NCT04280822RecruitingPhase 3
Immunotherapy plus chemo versus chemo alone before surgery
This Phase 3 trial tests whether adding immunotherapy to chemotherapy before surgery works better than chemotherapy alone for resectable esophageal cancer. The goal is to improve outcomes after tumor shrinkage before the operation.
Zhengzhou, HenanAges 18–75 - NCT03222895Recruiting
Mapping lymph node spread in resectable esophageal cancer
This study looks at how esophageal (or esophagus-stomach junction) cancer spreads to nearby lymph nodes. Results may help doctors understand where cancer cells are likely to be, potentially improving future surgery planning.
Houston, TexasAges 18 years+ - NCT06979869Recruiting
Esophageal cancer gene test for treatment response
This trial uses a blood test to track genetic changes in esophageal cancer over time. It aims to see if these changes can show how well treatment is working.
Wuwei, GansuAges 18–75 - NCT05357846RecruitingPhase 3
Check whether PD-1 treatment helps esophagus cancer before surgery
This Phase 3 trial tests whether adding a PD-1 medicine (sintilimab) to standard chemo-radiation before surgery improves outcomes for locally advanced esophageal squamous cell cancer. It may help by strengthening the immune response while shrinking the tumor before an operation.
Guangzhou, GuangdongAges 18–70 - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT06819566RecruitingPhase 2
Preventing bleeding from enlarged veins in the esophagus
This study tests whether tying off high-risk veins in the esophagus before starting a common liver cancer treatment can prevent bleeding. It is for people with liver cancer that has spread but who have never had cancer treatment before.
Seoul, Song-paAges 19–80 - NCT06173986RecruitingPhase 1/Phase 2
Immunotherapy plus chemoradiation for advanced esophageal cancer
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
ShanghaiAges 18–75 - NCT07217171RecruitingPhase 1
Study of EVOLVE104 for advanced bladder and squamous cell cancers
This trial tests an experimental drug called EVOLVE104 for people with advanced bladder cancer or certain types of squamous cell cancers. It aims to see if the drug is safe and if it can help shrink tumors.
Duarte, CaliforniaAges 18 years+ - NCT06869213RecruitingPhase 2
Adebrelimab plus chemo before and after surgery for esophageal cancer
This trial tests a combination of the immunotherapy drug adebrelimab (SHR-1316) and chemotherapy given before and after surgery for locally advanced esophageal squamous cell carcinoma that can be removed. The goal is to see if this approach helps shrink the tumor and improves outcomes.
BeijingAges 18–75 - NCT04135664RecruitingPhase 3
Compare surgery vs chemoradiation for early throat cancer
This study compares two ways to treat a type of esophagus cancer: surgical removal (esophagectomy) versus chemoradiation (chemo plus radiation). It is for people with early-stage findings where scans suggest no lymph node spread.
Nanchang, JiangxiAges 18–75 - NCT04652180Recruiting
Robot surgery versus open surgery for esophagus cancer
This trial compares robot-assisted surgery with the standard open chest operation to remove esophagus and nearby tissue. It may help you understand which approach works better and is safer for patients whose cancer can be surgically removed.
L'Hospitalet de Llobregat, BarcelonaAges 18 years+ - NCT06056336RecruitingPhase 2
Perioperative tislelizumab plus chemo for esophageal cancer
This trial tests whether giving tislelizumab (an immunotherapy) along with chemotherapy before and after surgery can help people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination improves outcomes for patients whose cancer is in the chest and can be removed with surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07863141RecruitingPhase 2
Maintenance therapy after first-line chemoimmunotherapy for advanced esophageal cancer
This study compares two maintenance treatments after initial chemotherapy plus immunotherapy for advanced esophageal squamous cell carcinoma. The goal is to see if adding anlotinib, a targeted drug that blocks blood vessel growth to tumors, to a PD-1 inhibitor is more effective than the PD-1 inhibitor alone.
Guangzhou, GuangdongAges 18–75 - NCT06304350RecruitingPhase 2
Pembrolizumab plus chemo before surgery for esophageal cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (given before surgery) can help shrink stage II/III esophageal cancer. The goal is to make surgery more likely to remove all cancer and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06410651RecruitingPhase 2
Nimotuzumab with chemoradiation for advanced esophageal cancer
This trial tests adding the targeted drug nimotuzumab to standard chemotherapy and radiation for people with esophageal cancer that cannot be removed by surgery. It may help shrink the tumor or stop it from growing further.
BeijingAges 18–80 - NCT06413342RecruitingPhase 2
Sintilimab after chemoradiation for older adults with esophageal cancer
This trial tests whether the immunotherapy drug Sintilimab can help prevent esophageal cancer from returning after standard chemotherapy and radiation. It is for patients aged 70-85 who cannot have or choose not to have surgery.
Hangzhou, ZhejiangAges 70–85 - NCT06646588RecruitingPhase 2
Study of fruquintinib, tislelizumab, and radiation for esophageal cancer
This trial tests a combination of two drugs (fruquintinib and tislelizumab) followed by radiation therapy for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach can help shrink tumors and improve outcomes.
Shijiazhuang, HebeiAges 18 years+ - NCT05894369Recruiting
Testing how the tumor environment affects pre-op chemo plus immunotherapy
This study looks at people with esophageal squamous cell carcinoma to see how changes in the “tumor neighborhood” may affect how well treatment works before surgery. If you’re eligible, you would receive chemotherapy plus immunotherapy as neoadjuvant (before-surgery) treatment.
Wuhan, HubeiAges 18–80 - NCT06718205RecruitingPhase 2
Nimotuzumab plus immunotherapy and chemo for esophageal cancer
This study tests a new combination of drugs for advanced esophageal cancer. It adds an antibody (nimotuzumab) and an immunotherapy (sintilimab) to standard chemotherapy, aiming to improve how well treatment works.
Zhengzhou, HenanAges 18–75 - NCT07108855RecruitingPhase 1/Phase 2
Green dye to guide early cancer removal
This trial tests whether a special dye (indocyanine green) given through a vein can help doctors see the exact edges and depth of early-stage esophageal or stomach cancer during a minimally invasive procedure to remove it. If you are scheduled for this procedure, the dye may help the surgeon remove the cancer more precisely.
Groningen, Provincie GroningenAges 18 years+ - NCT07061704RecruitingPhase 1/Phase 2
Oncolytic virus trial for esophageal cancer
This trial tests a virus-based therapy for locally advanced esophageal squamous cell carcinoma. It aims to see if the virus can target and kill cancer cells while sparing healthy tissue.
Chengdu, SichuanAges 18–80 - NCT07054086Recruiting
Personalized treatment testing with tumor models for esophageal cancer
This trial tests whether a personalized treatment plan, chosen using a lab-grown model of your tumor, works better than standard therapy for esophageal cancer that can be surgically removed. It aims to find the most effective drugs for you before surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06990178Enrolling by invitation
Adaptive Neoadjuvant Therapy for Esophageal Cancer
This trial is testing a new treatment approach for esophageal cancer that includes chemotherapy and immunotherapy before surgery. The goal is to see if this combination can help shrink the tumor and improve outcomes.
Shenzhen, GuangdongAges 18–75
Hear when a new Esophageal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for esophageal carcinoma?
- Yes. Clin2 currently lists 246 recruiting esophageal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a esophageal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a esophageal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Esophageal Squamous Cell Carcinoma
- Advanced Esophageal Squamous Cell Carcinoma
- Locally Advanced Esophageal Squamous Cell Carcinoma
- Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8
- Metastatic Esophageal Carcinoma
- Metastatic Esophageal Squamous Cell Carcinoma
- Resectable Esophageal Squamous Cell Carcinoma
- Advanced Esophageal Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.